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Abstract
Background: Chronic inflammation has been widely considered to be the major risk factor of coronary heart
disease (CHD). The goal of our study was to explore the possible association with CHD for inflammation-related
single nucleotide polymorphisms (SNPs) involved in cytosine-phosphate-guanine (CpG) dinucleotides. A total of 784
CHD patients and 739 non-CHD controls were recruited from Zhejiang Province, China. Using the Sequenom
MassARRAY platform, we measured the genotypes of six inflammation-related CpG-SNPs, including IL1B rs16944,
IL1R2 rs2071008, PLA2G7 rs9395208, FAM5C rs12732361, CD40 rs1800686, and CD36 rs2065666). Allele and genotype
frequencies were compared between CHD and non-CHD individuals using the CLUMP22 software with 10,000
Monte Carlo simulations.
Results: Allelic tests showed that PLA2G7 rs9395208 and CD40 rs1800686 were significantly associated with CHD.
Moreover, IL1B rs16944, PLA2G7 rs9395208, and CD40 rs1800686 were shown to be associated with CHD under the
dominant model. Further gender-based subgroup tests showed that one SNP (CD40 rs1800686) and two SNPs
(FAM5C rs12732361 and CD36 rs2065666) were associated with CHD in females and males, respectively. And the
age-based subgroup tests indicated that PLA2G7 rs9395208, IL1B rs16944, and CD40 rs1800686 were associated with
CHD among individuals younger than 55, younger than 65, and over 65, respectively.
Conclusions: In conclusion, all the six inflammation-related CpG-SNPs (rs16944, rs2071008, rs12732361, rs2065666,
rs9395208, and rs1800686) were associated with CHD in the combined or subgroup tests, suggesting an important
role of inflammation in the risk of CHD.
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Background
Coronary heart disease (CHD) is considered to be the
leading cause of mortality and morbidity in the elderly
[1]. CHD has emerged as a serious burden to human
health [2]. Both genetic and environmental factors were
shown to play an important role in the development of
CHD [3]. Environmental factors, including smoking and
dietary changes, were found to be associated with CHD
[4]. Heritable factors were estimated to contribute to
30–60 % of the variation in the risk of CHD [3]. In
addition, the incidence of CHD was generally higher in
men than in women regardless of their menopause type
[5]. Therefore, further exploration of the interactive
mechanism between genes and environment is much
more significant and helpful for specific diagnosis [6].
Increasing amount of evidence has indicated that
inflammation is responsible for CHD [7, 8]. Many
inflammation-related genes are found to be associated
with risk of CHD [9, 10]. Interleukin 1, beta gene
(IL1B) encodes the cytokine which exerts a wide
range of inflammatory activities [11]. Genetic association
between IL1B and CHD has been previously found [12].
Interleukin 1 receptor, type II (IL1R2) encodes a cytokine
receptor that belongs to the interleukin 1 receptor family
[13]. Notably, IL1R2 is recognized as a general factor in
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inflammatory response [14]. Phospholipase A2, group VII
(PLA2G7) gene encodes a kind of secreted enzyme [15],
and patients with high PLA2G7 expression was found to
have an increased risk of cardiovascular diseases [16]. Gene
polymorphisms in family with sequence similarity 5, mem-
ber C (FAM5C) gene were shown to be associated with an
increased risk of acute myocardial infarction [17], and ele-
vated FAM5C levels were found in atherosclerotic plaques
and coronary artery endothelium [18]. CD40 encodes a cell
surface receptor that plays a pivotal role in macrophage
activation and parasite immunity [19], and CD40 could
up-regulate prime macrophages through a proinflam-
matory program in recent studies [19]. CD36 encodes a
platelet receptor glycoprotein involved in different bio-
logical processes such as inflammation, atherosclerosis,
and platelet activation [20]. The association between
monocyte/macrophage CD36 and atherosclerosis has
been found in the previous studies [21].
Single nucleotide polymorphisms (SNPs) can change
biological properties of the encoded protein and affect
gene expression levels in an allele-specific manner
(24450106). Due to the mutability of cytosine-phosphate-
guanine (CpG) dinucleotides, CpG-SNPs, as an important
class of cis-regulatory polymorphisms, connect genetic
variation to the individual variability of the epigenome
[22]. CpG-SNPs in the promoter regions had been
found to be associated with multiple diseases, including
type 2 diabetes [23], breast cancer [24], schizophrenia
[25], and epithelial ovarian cancer [26]. In light of
previous studies, we aimed to evaluate whether the
six inflammation-related gene CpG-SNPs could con-
tribute to the risk of CHD.
Results and discussion
Genotypic and allelic tests were performed for a total of
six CpG-SNPs between CHD and non-CHD individuals
(Table 1). According to the most recent human assem-
bly, hg38/GRCh38, five CpG-SNPs (FAM5C rs12732361,
IL1R2 rs2071008, IL1B rs16944, CD40 rs1800686, and
CD36 rs2065666) were located upstream of the corre-
sponding transcription start sites (47, 178, 387, 508, and
659 bp, respectively). The remaining one (PLA2G7
rs9395208) was located in the 111 bp downstream of
transcription start sites.
As shown in Table 2, the genotype distributions of all
the six SNPs in the non-CHD controls met Hardy-
Weinberg equilibrium (HWE). Our results showed that
PLA2G7 rs9395208 and CD40 rs1800686 were signifi-
cantly associated with CHD on the allele level. The fre-
quency of allele rs9395208-G was significantly lower in
the case group than in the control (84.7 versus 87.3 %;
P = 0.04, OR = 0.806, 95 % CI = 0.657–0.991). Meanwhile,
a higher rs1800686-G frequency showed in the cases than
in controls (69.4 versus 65.4 %; P = 0.02; OR = 1.198, 95 %
CI = 1.029–0.394). No significant difference was observed
on the genotype level for all the CpG-SNPs (P > 0.05).
Gender disparities widely existed in the prevalence of
CHD [27], and female CHD patients aged 40 or older
have 10 % greater risk of death than the males [27].
Hence, we performed a gender-based subgroup analysis
Table 1 The list of genotyping primers for six CpG-SNPs
Gene SNP Primers Sequence (5′ to 3′)
IL1B rs16944 1st PCR primer ACGTTGGATGAGAGGCTCCTGCAATTGACA
2nd primer ACGTTGGATGCTGTCTGTATTGAGGGTGTG
Extend primer GGGGTGGGTGCTGTTCTCTGCCTC
IL1R2 rs2071008 1st PCR primer ACGTTGGATGGAAAAATCCATGCAGCCTCC
2nd primer ACGTTGGATGTGGTGGCTGACTTTCCAAGG
Extend primer TGGGAAGAAGCAAGCACCCC
PLA2G7 rs9395208 1st PCR primer ACGTTGGATGTGGACCCGCGGTTAACTTAG
2nd primer ACGTTGGATGATCAGGTCTGCGGAAAGGAG
Extend primer GCATTGCCTGGCTCT
FAM5C rs12732361 1st PCR primer ACGTTGGATGTTACACAGAGAGCCACGAAC
2nd primer ACGTTGGATGAGGATCACCACGAATCACCC
Extend primer GAAACCCCCACCATTCCCCA
CD40 rs1800686 1st PCR primer ACGTTGGATGATGGATGGGAAGTTGAGACG
2nd primer ACGTTGGATGCCCAACTCAGAATTTCGCTC
Extend primer GTCGCTTTCAAAGGAAATTCCCT
CD36 rs2065666 1st PCR primer ACGTTGGATGCTCTGAAGATATAATGACAAG
2nd primer ACGTTGGATGCAGTTTCTCTGTTCACTTCG
Extend primer CGTTCACTTCGTTTTAGTATAGAATTA
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to detect the difference both in genotype and allele
frequencies (Table 3). It showed significant associations of
FAM5C rs12732361 and CD36 rs2065666 with CHD
in males on the allele level (P = 0.03, OR = 1.266, 95 %
CI = 1.022–1.568; P = 0.04, OR = 0.806, 95 % CI = 0.652–
0.996, respectively). Meanwhile, CD40 rs1800686 was
shown to be significantly associated with CHD in females
(P = 0.02, OR = 1.347, 95 % CI = 1.043–1.740 by allele).
Age is another well-known risk factor in the develop-
ment and prognosis of CHD [28], and there were over
70 % of coronary-related deaths occurred in the people
older than 70 in North America and Western Europe
[28]. Therefore, we further evaluated the genotype and
allele frequencies in different age subgroups (Table 3).
For the individuals younger than 55, the frequencies of
both rs16944-G and rs2071008-G alleles were significantly
lower in case group than in control group (P = 0.01,
OR = 1.422, 95 % CI = 1.077–1.877; P = 0.04, OR = 0.733,
95 % CI = 0.538–1.000, respectively). For the individuals
with age between 55 and 65 years old, rs16944 was
associated with CHD on both genotype and allele levels
(χ2 = 6.15, P = 0.04 by genotype; P = 0.03, OR = 1.299, 95 %
CI = 1.022–1.653 by allele). Among the individuals older
than 55, rs1800686 was also shown to be associated
with CHD on both genotype and allele levels (genotype:
χ2 = 9.44, P = 0.009; allele: P = 0.003; OR = 1.456, 95 %
CI = 1.132–1.8740).
Additionally, we have conducted a comparison under
the dominant and recessive inheritance models between
cases and controls (Table 3). In the dominant model,
significant associations among rs16944, rs9395208 and
rs1800686 with CHD were observed. The rs16944-A
and rs1800686-A alleles were risk factors for CHD
(rs16944: P = 0.03, OR = 1.279, 95 % CI = 1.015–1.611;
rs1800686: P = 0.04, OR = 1.239, 95 % CI = 1.013–1.517).
The rs9395208-C allele was a protective factor for CHD
(P = 0.03, OR = 0.777, 95 % CI = 0.616–0.979). Meanwhile,
all the six CpG-SNPs showed no significant association
with CHD in the recessive model.
Besides, a post hoc power analysis showed that our
association study had strong power (93.9–94.1 %) to
detect significant association of the six CpG-SNPs
under an OR of 1.3.
The present study performed a comprehensive analysis
of association between six CpG-SNPs (IL1B rs16944, IL1R2
rs2071008, PLA2G7 rs9395208, FAM5C rs12732361, CD40
rs1800686, and CD36 rs2065666) and CHD. At the allelic
level, CD40 rs1800686-G was found to be a risk factor,
while PLA2G7 rs9395208-G was found to be a protective
factor. Moreover, all the CpG-SNPs were significantly asso-
ciated with the risk of CHD in the combined or subgroup
analyses.
Inflammation represents an important feature in the
process of atherosclerosis, which can form, destabilize,
and rupture atherosclerotic plaques, finally causing CHD
[29]. Over the years, researchers have found some inflam-
matory factors related to the pathogenesis and prognosis
of CHD, such as CLOCK SNP rs4580704 [30], ICAM-1
Table 2 Comparisons of genotype and allele frequencies between cases and controls
SNP Groups Genotype (counts) χ2 P (df = 2) HWE P valuea Allele (counts) χ2 P (df = 1) OR (95 % CI)
IL1B rs16944 GG AG AA G A
Cases 220 380 176 0.627 820 732
Controls 173 379 180 4.387 0.112 0.335 725 739 3.310 0.069 1.142 (0.990–1.317)
IL1R2 rs2071008 GG GT TT G T
Cases 434 285 65 0.064 1153 415
Controls 417 275 46 2.382 0.304 0.941 1109 367 1.020 0.313 0.919 (0.781–1.082)
PLA2G7 rs9395208 GG GC CC G C
Cases 565 198 21 0.468 1328 240
Controls 568 154 17 4.603 0.100 0.095 1290 188 4.210 0.040 0.806 (0.657–0.991)
FAM5C rs12732361 GG AG AA G A
Cases 492 242 49 0.011 1226 340
Controls 431 254 52 3.022 0.221 0.088 1116 358 2.850 0.091 1.157 (0.977–1.370)
CD40 rs1800686 GG AG AA G A
Cases 378 332 74 0.929 1088 480
Controls 317 333 89 5.411 0.067 0.914 967 511 5.440 0.020 1.198 (1.029–1.394)
CD36 rs2065666 GG GC CC G C
Cases 439 288 56 0.356 1166 400
Controls 411 282 43 1.24 0.538 0.555 1104 368 0.120 0.729 0.972 (0.825–1.145)
aHWE Hardy-Weinberg equilibrium; P value <0.05 was considered a departure from HWE
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SNP rs281432 [31], and NFKB1 SNP rs28362491 [32].
Some of these inflammation-related genes were expected
to be drug targets for the control and treatment of CHD.
Meanwhile, we hypothesized that hereditable methylation
could be associated with CHD. Because of low minor
allele frequency or weak haplotype associations, genome-
wide searches for genetic risk factors for CHD have in
general not investigated the CpG-SNPs. Our previous
work [33] indicated that CpG-SNPs of the thrombotic
pathway genes contributed to the risk of CHD, which
suggested a clue for investigating the contributions of
the inflammation-related CpG-SNPs to the susceptibility
to CHD.
PLA2G7 gene encodes a secreted enzyme whose activity
is associated with CHD [34]. PLA2G7 functions as a
biomarker of plaque inflammation and stability [35].
Several PLA2G7 SNPs (e.g., rs7756935, rs1805017,
and rs13210554) have been reported on the susceptibility
to CHD [35, 36]. Here, we discovered a significant
association of PLA2G7 CpG-SNP rs9395208 with CHD,
even in the individuals aged ≤55, providing additional
evidence of age dimorphism in the risk of CHD. Add-
itionally, Jiang et al. [15] have reported that the correl-
ation between PLA2G7 methylation and CHD risk in
females is independent of age, smoking, diabetes, and
hypertension, which indicated a close relationship be-
tween PLA2G7 and hereditable methylation in the
pathogenic mechanism of CHD.
The contribution of CD40 rs1800686 is another main
finding in the current study. CD40 is considered to de-
termine T cell responses to antigen presentation and B
cells immunoglobulin isotype switching, which plays a
key role in the inflammatory and prothrombotic processes
by bonding with CD40 ligand (CD40L) in atherosclerosis
[37]. Previous study provided evidence of association of
CD40 rs1883832 with an overall increased risk of CHD in
Chinese population [38]. In the current study, a similar re-
sult was drawn that CD40 rs1800686-A allele contributed
Table 3 A list of SNPs associated with CHD in the subgroup tests
Gene SNP Model or subgroup Group Genotype or allele (counts) χ2 P (df) OR (95 % CI)
IL1B rs16944 Dominant Cases GG/GA + AA (220/556) 4.350 0.037 (1) 1.279 (1.015–1.611)
Controls GG/GA + AA (173/559)
IL1B rs16944 ≤55 years of age Cases G/A (236/236) 6.190 0.013 (1) 1.422 (1.077–1.877)
Controls G/A (292/248)
IL1B rs16944 55–65 years of age Cases GG/GA/AA (79/134/57) 6.147 0.046 (2)
Controls GG/GA/AA (53/145/66)
IL1B rs16944 55–65 years of age Cases G/A (292/248) 4.560 0.033 (1) 1.299 (1.022–1.653)
Cases G/A (251/277)
IL1R2 rs2071008 ≤55 years of age Controls G/T (254/106) 3.860 0.049 (1) 0.733 (0.538–1.000)
Cases G/T (366/112)
PLA2G7 rs9395208 Dominant Cases GG/GC + CC (565/219) 4.590 0.032 (1) 0.777 (0.616–0.979)
Controls GG/GC + CC (568/171)
PLA2G7 rs9395208 ≤55 years of age Cases G/C (295/65) 5.750 0.016 (1) 0.627 (0.427–0.920)
Controls G/C (420/58)
FAM5C rs12732361 Male Cases G/C (849/225) 4.660 0.031 (1) 1.266 (1.022–1.568)
Controls G/C (629/211)
CD40 rs1800686 Female Cases G/A (354/138) 5.230 0.022 (1) 1.347 (1.043–1.740)
Controls G/A (417/219)
CD40 rs1800686 Dominant Cases GG/GA + AA (378/406) 4.340 0.037 (1) 1.239 (1.013–1.517)
Controls GG/GA + AA (317/422)
CD40 rs1800686 ≥65 years of age Cases GG/GA/AA (163/146/24) 9.437 0.009 (2)
Controls GG/GA/AA (90/109/32)
CD40 rs1800686 ≥65 years of age Cases G/A (472/194) 8.600 0.0034 (1) 1.456 (1.132–1.874)
Controls G/A (289/173)
CD36 rs2065666 Male Cases G/C (790/286) 4.000 0.046 (1) 0.806 (0.652–0.996)
Controls G/C (641/187)
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to CHD risk. Age and gender are considered as two
independent risk factors in CHD [28, 39]. Subsequent
subgroup analysis identified age and gender differences
existed in the rs1800686, which revealed an age- and
gender-based mechanism on the genetic variations.
As a scavenger receptor, CD36 is not only involved in
the metabolism of lipids but also plays an important role
in the adhesion of negatively charged macromolecules
[40]. CD36 is widely expressed in cells and tissues in-
cluding microvascular endothelial cells, monocytes, and
macrophages [41]. Previous study implied that increased
CD36 expression level could reflect the severity of
coronary artery atherosclerosis [42]. Several CD36 SNPs
(e.g., rs5956, rs3173798, and rs3211892) have been re-
ported to be associated with CHD [42]. Here, we detected
a significant protection role of CD36 CpG-SNP rs2065666
G carries in CHD male patients. Our data suggested a
possible molecular mechanism through which SNP could
influence a phenotype.
Interleukins (IL-1B and IL1R2) were shown to play a
role in the inflammatory response, and they lead to the
development of atherosclerotic plaques [43, 44]. Re-
cently, gender dimorphism was observed in the associ-
ation of IL-1B polymorphism with CHD [45]. We find
no significant difference on IL-1B rs16944 allele or geno-
type level by gender subgroup analysis. However, age-
based subgroup tests showed that IL-1B rs16944-G was
a risk factor of CHD in younger population, while IL1R2
rs2071008-G was a protective factor. Further validation
study or functional analysis of these variants is needed
in the future.
Increased expression of FAM5C may be induced by in-
flammatory stimuli [17]. This case-control study observed
significant associations between FAM5C rs12732361
polymorphisms and CHD only in males. Due to a lack of
CHD study on FAM5C, more investigations are needed to
validate our results.
There are also limitations in the current study. The
findings of our study are limited to a small population
with documented CHD and cannot be generalized to the
population at large. Although we found positive results
in the current study, the power effect might be reduced
by strict multiple adjustment or subgroup analyses.
Therefore, larger sample size and other ethnic popula-
tions are required to be investigated.
Conclusions
In conclusion, our case-control study suggested that the
six inflammation-related CpG-SNPs were significantly
associated with the risk of CHD in the combined or the
subgroup samples. Moreover, our results also revealed that
IL1B rs16944, PLA2G7 rs9395208, and CD40 rs1800686




A total of 784 CHD patients and 739 healthy controls
were collected from Ningbo First Hospital of Ningbo Uni-
versity between May 2008 and April 2015 in Zhejiang
province, China. CHD patients and non-CHD controls
were defined as described before [33, 46]. Patients with
congenital heart disease, cardiomyopathy, liver disease,
and renal disease were excluded. Blood samples were col-
lected in 3.2 % citrate sodium-treated tubes and processed
in the central clinical laboratory of the hospital. All the
participants provided written informed consent form
under a protocol approved by the Medical Ethics Commit-
tees of Ningbo First Hospital and Ningbo University.
SNP selection and genotyping
The selected CpG-SNPs are on the promoter of
inflammation-related genes. Meanwhile, the minor allele
frequencies of the selected CpG-SNPs are over 10 % in
HapMap HCB population. CpG-SNPs with design prob-
lems or failed assays were excluded. Finally, six CpG-SNPs
in inflammation-related genes were included in the current
study. DNA extraction and quantification were described
as previously [33, 46]. The polymerase chain reaction
(PCR) amplification was performed on the GeneAmp®
PCR System 9700 (Applied Biosystems, Foster City, CA,
USA), and the genotyping was performed on the MassAR-
RAY iPLEX® assay platform (Sequenom, San Diego, CA,
USA). The sequences of the amplification and extension
primers for the six CpG-SNPs were shown in Table 1.
Statistical analyses
Genotype and allele frequencies of the polymorphisms be-
tween cases and controls were calculated by the
CLUMP22 software with 10,000 Monte Carlo simulations
[47]. The distribution of Hardy-Weinberg equilibrium
(HWE) was tested using the Arlequin program (version
3.5, Bern, Switzerland), and P > 0.05 was considered to be
in HWE. Power analysis was performed using the Power
and Sample Size Calculation software (v3.0.43). A two-
tailed P < 0.05 was considered statistically significant.
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